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Abstract
Serogroup X meningococci (NmX) historically have caused sporadic and clustered meningitis cases in sub-Saharan Africa. To
study recent NmX epidemiology, we analyzed data from population-based, sentinel and passive surveillance, and outbreak
investigations of bacterial meningitis in Togo and Burkina Faso during 2006–2010. Cerebrospinal fluid specimens were
analyzed by PCR. In Togo during 2006–2009, NmX accounted for 16% of the 702 confirmed bacterial meningitis cases. Kozah
district experienced an NmX outbreak in March 2007 with an NmX seasonal cumulative incidence of 33/100,000. In Burkina
Faso during 2007–2010, NmX accounted for 7% of the 778 confirmed bacterial meningitis cases, with an increase from 2009
to 2010 (4% to 35% of all confirmed cases, respectively). In 2010, NmX epidemics occurred in northern and central regions of
Burkina Faso; the highest district cumulative incidence of NmX was estimated as 130/100,000 during March–April. Although
limited to a few districts, we have documented NmX meningitis epidemics occurring with a seasonal incidence previously
only reported in the meningitis belt for NmW135 and NmA, which argues for development of an NmX vaccine.
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Introduction
In the African meningitis belt, Neisseria meningitidis serogroup A
(NmA) is associated with seasonal hyperendemic and epidemic
meningitis, but other meningococcal serogroups, pneumococci,
and Haemophilus influenzae type b contribute to the meningitis
burden. In 2002 for example, NmW135 was responsible for an
epidemic wave in Burkina Faso with about 13,000 cases [1], and
the same sequence type ST-11 was found as the main agent during
an outbreak in southern Niger during 2009 [2].
During the last two decades, sporadic cases of serogroup X
(NmX) meningitis have occurred throughout the meningitis belt.
Niger reported cases during 1990 [3] and 1997, with the detection
of 83 confirmed cases in Niamey [4]. In northern Ghana during
2000, 7 NmX cases and a concomitant increase of NmX carriage
were reported [5,6]. In 2006, from January to June, an outbreak
with over 550 NmX cases occurred in the south-western region of
Niger including Niamey [7]. During the same year, 11 NmX were
reported in north-eastern Uganda [8] and 5 in the bordering
districts of Kenya [9]. Nevertheless, NmX has not been docu-
mented to cause outbreaks of the magnitude previously associated
with NmA and NmW135.
While some meningococcal polysaccharide or conjugate
vaccines now include serogroup W135, no vaccine currently exists
against serogroup X. Some studies to define natural immunity
to NmX [Amadou et al., 17
th International Pathogenic Neisseria
Conference; Banff, Canada; 2010 Sep 11–16; Abstract P108] and
to identify correlates of protection and purify the polysaccharide
(G. Norheim, personal communication) are ongoing, but no larger
development project for an affordable vaccine exists. Lack of an
NmX vaccine would be less relevant if hyperendemic cases and
smaller outbreaks occurred only sporadically. However, a vaccine
for epidemic response or prevention would be needed if NmX
caused epidemics similar to NmAo rNmW135. To address this
issue, we analyzed incidence, microbiological and clinical data to
determine NmX burden and epidemiological patterns in Burkina
Faso and Togo during 2006–2010.
Methods
Ethics statement
The decision to perform lumbar punctures was made by the
treating health care providers. The national Burkina Faso and
Centre Muraz ethics committees approved the Bobo-Dioulasso
surveillance study protocol, for which informed written consent
was obtained from participants, as we collected individual data
beyond that obtained for routine national surveillance. All other
surveillance activities were part of the national surveillance systems
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Burkina Faso Ministries of Health; as these systems were part of
routine public health surveillance, ethical committee approval and
informed consent were not sought.
Surveillance activities
We used data from surveillance activities in Togo and Burkina
Faso (Figure 1), based on polymerase chain reaction (PCR) as the
principal diagnostic technique. Activities were implemented in
collaboration with local Ministries of Health.
In Togo, January 2006–September 2009, we conducted sentinel
surveillance in major referral hospitals situated in To ˆne district
(regional hospital of Savanes region), Kozah district (regional
hospital of Kara region), Tchaoudjo district (regional hospital of
Central region) and Soutouba district (district hospital) [10]
(Figure 1A). Each site had a theoretically covered population
of 150,000 to 300,000 (in total about 15% of the Togolese
population). Togo is situated at the southern border of the
meningitis belt and, while the Savanes region in the north has a
long dry season from November to May with hyperendemic
meningitis incidence, Kara and Centrale region have a less
pronounced dry season depending on inter-annual variations of
the inter-tropical convergence zone [11]. All persons presenting
with suspected acute bacterial meningitis at one of the sentinel sites
received a lumbar puncture. The number of cases included during
the sentinel surveillance was about 50% higher than the number of
cases routinely reported. Cerebrospinal fluid (CSF) was evaluated
by culture and by PCR.
In Burkina Faso, we conducted a surveillance study in 4 sanitary
districts (865,000 inhabitants, about 6% of the Burkinabe `
population), around Bobo-Dioulasso March 2007–December
2009. As previously published [12], all suspected meningitis
patients presenting at any health center or hospital received a
lumbar puncture and the corresponding CSF was analyzed by
culture, latex agglutination and PCR. The number of cases
included during the surveillance study was nearly 20% higher than
the number of cases routinely reported in these districts.
In western Burkina Faso, passive surveillance has been
conducted since February 2009 in 10 districts (Figure 1B). We
provided assistance so that all health centers of the participating
districts could send CSF samples from all suspected meningitis
cases for PCR analysis. The theoretically covered population
was 2,397,200 (15.5% of the total Burkinabe ` population). We
evaluated 35% of routinely reported cases in these districts.
Lastly, outbreak investigations to define meningitis etiology
were conducted throughout Burkina Faso using a mobile
laboratory equipped with bacteriology facilities for immediate
analysis [13]. CSF samples were also analysed by PCR. Twenty-
two outbreak investigations were thus conducted among 78
epidemic district declarations during 2007–2010.
For all surveillance activities, we used the WHO case definition
for suspected bacterial meningitis (sudden onset of fever .38.5uC
rectal and meningeal signs such as neck stiffness, bulging fontanel,
convulsion, vomiting or other) [14]. Lumbar puncture was
performed by the treating nurse or physician in the health center
or hospital. Patient age and CSFappearance wereavailable from all
surveillance systems. Information on clinical outcome (death, severe
complications during hospitalization such as shock or coma, and
persistent motor-sensorial deficit at hospital discharge) was available
from Togo and the surveillance study around Bobo-Dioulasso.
Figure 1. Surveillance systems in Togo and Burkina Faso. A. Togo: sentinel surveillance sites in Dapaong, Kara, Sokode ´ and Soutouba during
2006–2009. B. Burkina Faso: 2009–2010 passive surveillance in the western country (light grey); 2007–2010 surveillance study (dark grey); 2007–2010
mobile laboratory outbreak investigations (dark dots).
doi:10.1371/journal.pone.0019513.g001
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ningococcal serogroup A/C polysaccharide vaccine were per-
formed in Savanes and Kara regions (Togo) during 2006–2010,
and reactive mass campaigns using the same vaccine in Burkina
Faso during 2006–2008 to cover all districts of the country.
Laboratory analysis
All bacteriological analyses were performed by standard
methods [14]. A multiplex technique was used for PCR analyses
at Centre Muraz in Bobo-Dioulasso [12], which involved gene
amplification of crgA for Nm, bexA for Haemophilus influenzae (Hi), lytA
for Streptococcus pneumoniae (Sp), siaD for Nm genogroups B, C, Y, X,
and W135, and mynB for NmA. The WHO Collaborating Center
at the Institut de Me ´decine Tropicale du Service de Sante ´ des
Arme ´es (IMTSSA, France) performed phenotyping and multi-
locus sequence typing as previously described [15] on a selection of
28 Nm isolates and on CSF from 10 persons with NmX meningitis,
as no NmX isolates had been stored.
Data analysis
All statistical analyses were performed using STATA 10.0
(StataCorp, College Station, TX, USA). We calculated cumulative
weekly, monthly and seasonal incidences as number of reported or
confirmed cases for specific weeks, months or the total meningitis
season (January through May), divided by the population
estimated provided by the sanitary authorities for the surveyed
population. For Se ´gue ´ne ´ga district, we calculated serogroup-
specific district incidence from the incidence of suspected cases
reported by Ministries of Health multiplied by the percentage of
NmX among all suspected cases identified by laboratory analyses in
the sentinel sites. 95%-confidence intervals (95%-CI) to these
estimates were calculated using the formula Var(X,Y) = Var(X)
Var(Y) + Var(X) E[Y]
2 + E[X]
2 Var(Y) for the multiplication of
variances. To compare the association of outcomes with
epidemiological characteristics of cases, we defined a variable
encompassing five categories based on the serogroup and
epidemiological context (e.g., ‘‘epidemic NmA’’, ‘‘non epidemic
NmA’’, ‘‘NmX Centrale’’ for cases from outside the meningitis
belt).The epidemic context in the districts was defined based upon
national reporting and the WHO thresholds for epidemics [14].
We tested for differences in case characteristics between
serogroups X and A using the Chi-square test and an alpha error
of 5%. In addition, we performed multivariate logistic regression
analyses to estimate the association of serogroup X or A meningitis
with (i) age group, controlling simultaneously for sex, epidemic
situation and country; and (ii) death or sequelae, controlling
simultaneously for age group, sex, epidemic situation, and CSF
aspect (Togo only). Multivariate logistic regression analyses
included suspected cases identified in sentinel surveillance in
Togo, the Bobo-Dioulasso surveillance study and passive surveil-
lance in western Burkina Faso. Results are reported as odds ratios
(OR) with 95% confidence interval (95%-CI).
Results
Togo 2006–2009
During the surveillance period, 1,376 suspected cases were
identified, of which 1,044 (76%) were tested by PCR. A bacterial
etiology was confirmed for 702 (51%), of which 428 (61%) were
Nm. Overall, NmA and NmX accounted for 31% (N=219) and
16% (N=114) of confirmed cases, respectively, and this figure
varied by region and year (Figure 2A). Within sites and years,
NmA and NmX did not occur simultaneously. Four percent of NmX
and 18% of NmA cases occurred in a non-epidemic context.
During the 2007 meningitis season, To ˆne and Kozah districts
declared epidemics. In To ˆne district (281,303 inhabitants), among
316 suspected and 258 confirmed bacterial cases, 196 (76%) were
identified as NmA, 32 (12%) Sp,1 2NmW135, 9 non-groupable Nm,
8 Hi and 1 NmX( Figure 2A). The peak monthly NmA cumulative
incidence per 100,000 was 49 (95%-CI, 41–58) during March and
the seasonal incidence 70 (95%-CI, 60–80). In Kozah district,
(224,398 inhabitants), among 172 suspected and 97 confirmed
bacterial cases, 75 were NmX (77%), 8 NmW135 (8%), 7 Sp (7%), 5
non-groupable Nm (5%), 2 Hi (2%) and none NmA( Figure 2A).
The NmX peak monthly incidence per 100,000 was 24 (95%-CI,
18–31) during March and the NmX seasonal incidence 33 (95%-
CI, 26–42).
In the Kozah NmX outbreak, based on 46 persons with NmX
meningitis and accurate information on residence, 78% of cases
(N=36) were localized within an approximately 60 km
2 triangle,
bounded by Kara City and the 2 main roads going north
(Figure 3). Three overlapping waves of NmX occurrence could be
described: first in north-eastern Kozah district from week 3 to 12
(N=11), then in Kara City which reported half of the total cases
mostly during week 9 to 11 (N=18), and lastly in north-western
Kozah district from week 10 to 13 (N=7).
During the following 2 years, no meningitis epidemic was
reported in Savanes or Kara regions. During this period, in the
Savanes region, NmA accounted for 22 cases (69% of all Nm
detected cases), whereas 9 (28%) were NmW135 and only one
NmX case was observed. In the Kara region, six of the 15 Nm cases
were NmX, 3 were NmW135 and 1 NmA.
In the Centrale region, which is situated outside the meningitis
belt, 24 and 25 Nm cases were seen during the 2007 and 2008
seasons, respectively, with 15 NmX cases each year. No NmA case
and only rare sporadic NmW135 cases were detected throughout
the entire surveillance period (Figure 2A).
Burkina Faso 2007–2010
Population-based surveillance. In the Bobo-Dioulasso
surveillance study, a total of 1,008 suspected cases were included
during March 2007–December 2009, with 976 CSF analyzed.
Among 455 cases with confirmed bacterial etiology (47% of all
suspected cases) (Figure 2B), 286 (63%) were due to Nm, 159
(35%) to Sp and 9 (2%) to Hi. Of the 286 Nm cases, 269 (94%) were
NmA, 9 (3%) non-groupable Nm, 5 (2%) NmW135, 2 (1%) NmX
and 1 NmC( ,0.5%).
Passive surveillance. During 2009–2010, 633 CSF were
collected and 203 (32%) confirmed for a bacterial etiology. During
2009, 80 (87%) of 92 confirmed cases were Sp, 6 (7%) NmA, 4 (4%)
Hi, one (1%) non-groupable Nm and one (1%) NmX, while in 2010,
of 111 confirmed cases, NmX accounted for 44 (40%), Sp for 52
(47%), NmA for 9 (8%), NmW135 for 4 (4%) and Hi for 2 cases (2%).
Outbreak investigations. For 49 (16%) of the 301 collected
CSF, an etiology was confirmed by PCR. During 2007 and 2008,
among the 83 confirmed cases, 79 (95%) were NmA and 4 (5%) Sp.
During 2009, among 9 confirmed cases with etiologic
confirmation, 6 were NmX, 2 Sp and 1 NmA. During the 2010,
59 CSF were collected in western and northern regions; of 28
confirmed cases, 5 (18%) were NmX, 21 (75%) NmA, 2 (7%) non-
groupable Nm and none Sp.
In Se ´gue ´ne ´ga district in northern Burkina Faso, April 2009,
CSF was collected from 12 suspected cases, of which 5 were NmX
and 1 Sp. During March-April 2010, this district reported 259
suspected cases for 179,200 inhabitants, corresponding to a
cumulative incidence of 145/100,000. Of six suspected cases
evaluated during week 11 (34 cases reported by the national
surveillance), five were NmX and one had no etiology confirmed.
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120 (95%-CI, 75–166) per 100,000 during March–April and a
weekly NmX incidence of 16 (95%-CI, 8–24) per 100,000 during
week 11. In addition to Se ´gue ´ne ´ga, seven other Burkina Faso
districts declared an epidemic during 2010, in two of which our
surveillance activities allowed to identify the causative agent: in
Toma district we detected 21 NmX, 5 NmA and 10 Sp among 74
suspected cases, while in Titao (district, neighboring Se ´gue ´ne ´ga)
we detected 21 NmA and 1 Sp among 49 suspected cases
(Figure 4).
Overall, during 2007 to 2010, NmX accounted for 7% (N=57)
of the 778 confirmed cases, with an increase from 2009 (N=7; 4%
of all confirmed cases) to 2010 (N=49; 35% of all confirmed
cases). Twenty eight percent of NmX and 59% of NmA cases
occurred in a non-epidemic context.
Characteristics of NmX cases
Information on age and sex was available for 168 NmX and 530
NmA cases, and on clinical outcomes at hospital discharge for 98
NmX and 426 NmA cases (Table 1). Age and sex distribution
did not differ significantly between NmX and NmA cases in
comparable epidemic contexts. Across serogroups, epidemiological
contexts and countries, children between 5 and 14 years of age
contributed most to meningococcal disease burden (36%–77% of
cases). In Burkina Faso during epidemics, females were under-
represented among NmX compared to NmA cases (27% vs. 56%,
P=0.019), but this was not observed in Togo. In both settings,
NmX cases tended to present less frequently with visibly purulent
CSF aspect (NmX vs. NmA, 81.1% vs. 91.6%, P,0.000). In
multivariate analyses among all suspected cases, compared to 5- to
14-year-old children, diagnosis of NmX was less likely in infants
,1 year (OR 0.30, 95%-CI 0.88–1.03) and young adults 15–29
years of age (OR 0.55, 95%-CI 0.31–0.97), while diagnosis of NmA
was more likely in these age groups (OR 3.28, 95%-CI 0.96–11.26
for infants and OR 1.83, 95%-CI 1.03–3.27 for young adults).
Information on clinical outcomes of both NmA and NmX cases
was available in substantial number mostly from Togo. No
significant difference was seen between NmX and NmA for severe
complications or motor-sensorial deficit (7% vs. 12%, P=0.206),
and fatal outcome tended to occur more frequently in NmX than
NmA cases (16% vs. 10%, P=0.120). Compared to NmX cases
occurring in an epidemic context from other regions in Togo,
Figure 2. Number of confirmed bacterial meningitis cases, by etiology. A. Togo: sentinel hospital-based surveillance in three sanitary
regions 2006–2009. B. Western Burkina Faso: exhaustive and passive surveillance and outbreak investigations, 2007–2010. Sp: Streptococcus
pneumoniae, Nm: Neisseria meningitides.
doi:10.1371/journal.pone.0019513.g002
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case fatality (28.6% vs. 10.8%, P=0.028) and more frequent
severe complications or motor-sensorial deficit (17.7% vs. 4.0%,
P=0.040). In general, irrespectively of serogroup or country, cases
occurring during epidemics tended to be associated with lower
case fatality and less severe outcome than those that occurred in a
non-epidemic context. In multivariate analyses including all NmA
and NmX cases confirmed in Togo, compared to NmA, serogroup
X caused substantial but insignificant negative association with
observation of severe complications or motor-sensorial deficit (OR
0.41, 95%-CI 0.13–1.28), and none with mortality (OR 1.01,
95%-CI 0.42–2.42). Among NmX cases, fatal outcome was
associated with persons aged 30 years or older (OR 4.89, 95%
CI 2.00–11.92 compared to age 5–14 yrs).
Phenotype and sequence type
Multi-locus sequence typing described ST-181 for all 10 CSF
samples tested from the Kozah outbreak. One NmX isolate from
Bobo-Dioulasso, 2007, was X:NT: P1.5, ST-181. Among 48 NmA
isolates tested (found in Togo and Bobo-Dioulasso, 2007–2008),
45 were A:4:P1.9, ST-2859. The remaining three, all found in
Bobo-Dioulasso, 2008, were a new sequence type ST-6968 (single-
locus variant of ST-2859). One NmW135 isolate found in Bobo-
Dioulasso, 2007–2008, was W135:NT:P1.5,2, ST-2881.
Discussion
This analysis of surveillance data from Togo and Burkina Faso
during 2006–2010 confirms that NmX not only causes small
outbreaks and sporadic meningitis cases during seasonal hyper-
endemicity, but has epidemic potential. In two districts of Burkina
Fasoduring2010andone inTogo2007,NmXwasthepredominant
etiology, representing 56% of laboratory-confirmed bacterial
meningitis cases, while incidences were above the epidemic
threshold [14]. In Burkina Faso during 2010, the NmX cumulative
incidence during March-April was 120 (95%-CI, 75–166) per
100,000 in the Se ´gue ´ne ´ga district, and the seasonal cumulative
incidence likely was even higher. Previously observed district NmX
seasonal cumulative incidences per 100,000 were 28 (95%-CI, 24–
31)inNiamey/Niger[7]and 33(95%-CI,26–42)inKozahdistrict/
Togo. Consequently, the current report represents the first NmX
epidemic with a seasonal incidence comparable to NmA epidemics
previously observed in western Burkina Faso [e.g., Secteur 15
district 2006 with 110 (95%-CI, 100–121) per 100,000, AMP/
Centre Muraz authors, unpublished data] or Togo [To ˆne district
2007 with 70 (95%-CI, 60–80) per 100,000], where eventually
appropriate reactive vaccine mass campaigns were launched for
epidemic control. Although data were not available for this report,
NmX was identified as the epidemic agent in three additional
districts of Burkina Faso that declared an epidemic in 2010 and
NmX cases were found in 15 districts, of which 10 were
characterized by complete absence of NmA cases during this season
[Delrieu et al., 17
th International Pathogenic Neisseria Conference;
Banff, Canada; 2010 Sep 11–16; abstract OM11]. The 2010 NmX
epidemics occurred in a few districts, and not in the form of a
geographically expansive epidemic wave spanning several regions
or countries. By contrast, NmA has historically caused large
epidemics, as did NmW135 during 2002. As with any other
Figure 3. Spatio-temporal epidemiology of the NmX outbreak in the Kozah district, Togo, 2007. A. Geographical distribution of 39 NmX
cases with information on patient residence. Three zones were determined: Kara City, North West of Kara City (NW) and North East of Kara City (NE).
Each red star represents one confirmed NmX case. B. Weekly identification of NmX cases, from January to June 2007 (36 cases with information
available on both patient residency and month of CSF collection). Nm: Neisseria meningitides.
doi:10.1371/journal.pone.0019513.g003
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19513Figure 4. District level etiology distribution among PCR-confirmed bacterial meningitis cases from surveillance in Burkina Faso,
2010. Circle size is proportional to the seasonal cumulative incidence in the districts (January–June). Black spots indicate districts with reported
epidemics during 2010. The white colored circles are epidemic districts for which the etiology distribution is not available for this report. Numbersi n
circles represent the total number of confirmed cases in epidemic districts if the total number was less than 15.
doi:10.1371/journal.pone.0019513.g004
Table 1. Epidemiological characteristics of NmA and NmX confirmed cases of meningitis, by country.











Female: % (N) BF 39 (222) 46 (114) 38 (181) 49 (75) 41 (41) 50 (8) 39 (31)
T 41 (309) 28 (57) 56 (39) 27 (26) 39 (270) 29 (31) n/a
Age group (years): % (N) ,1 BF 9 (221) 2 (114) 8 (180) 1 (75) 12 (41) 12(8) 0 (31)
T 5 (310) 2 (54) 0 (39) 0 (26) 6 (271) 4 (28) n/a
1–4 BF 17 (221) 15 (114) 17 (180) 15 (75) 17 (41) 25 (8) 13 (31)
T 21 (310) 19 (54) 23 (39) 15 (26) 20 (271) 21 (28) n/a
5–14 BF 45 (221) 49 (114) 47 (180) 51 (75) 37 (41) 36 (8) 48 (31)
T 52 (310) 72 (54) 64 (39) 77 (26) 50 (271) 68 (28) n/a
15–29 BF 22 (221) 18 (114) 22 (180) 16 (75) 20 (41) 25 (8) 23 (31)
T 19 (310) 7 (54) 13 (39) 8 (26) 20 (271) 7 (28) n/a
$30 BF 8 (221) 16 (114) 6 (180) 17 (75) 15 (41) 0 (8) 16 (31)
T 3 (310) 0 (54) 0 (39) 0 (26) 4 (271) 0 (28) n/a
Visibly purulent CSF: % (N) BF 93 (216) 86 (112) 92 (177) 84 (75) 100 (39) 71 (7) 93 (30)
T 91 (311) 71 (52) 95 (39) 71 (21) 90 (272) 71 (31) n/a
Severe complication or motor-
sensorial deficit *: % (N)
BF 12 (198) 7 (96) 10 (177) 4 (75) 29 (21) 25 (4) 18 (17)
T 6 (230) 0 (2) 5 (19) n/a 6 (211) 0 (2) n/a
Death: % (N) BF 10 (214) 16 (108) 8 (177) 11 (74) 16 (37) 17 (6) 29 (28)
T 10 (268) 0 (2) 5 (20) n/a 10 (248) 0 (2) n/a
BF is for Burkina Faso data; T is for Togo data. Nm: Neisseria meningitis.
*Severe complication: coma or shock during hospitalisation; motor-sensorial deficit as observed at hospital discharge.
doi:10.1371/journal.pone.0019513.t001
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such epidemic waves [16]. If NmX epidemics occurred regularly or
covered larger regions, reactive or preventive vaccination could be
deemed efficient from the public health perspective. Our analysis
did not provide evidence for substantial differences in demographic
characteristics or clinical outcomes between NmA and NmX cases,
therefore preventive strategies against NmX should target the same
groups as against NmAo rNmW135.
The NmX sequence type (ST-181) that was responsible for the
Kozah outbreak has been identified in the meningitis belt for
several decades, first in carriage in Mali in the 1970s [17] and in
invasive isolates in Niger, 1997 [4]. The majority of NmX invasive
isolates from West Africa since 2000 belonged to this sequence
type [17,18], which more recently was found in carriage in Bobo-
Dioulasso in 2008 (X:15:P1.6, ST-198) [Njanpop-Lafourcade
et al., 17
th International Pathogenic Neisseria Conference; Banff,
Canada; 2010 Sep 11–16; abstract P051]. ST-751, a genetically
related sequence type [5], was found in sporadic cases and carriage
in Bobo-Dioulasso during 2003 [15]. However, the longstanding
and continuous presence of ST-181 NmX strains in the meningitis
belt, especially during recent years, with and without occurrence of
epidemics, suggests that factors other than strain virulence are
involved in the occurrence of NmX epidemics [19].
The finding that in 2010, Se ´gue ´ne ´ g ad i s t r i c te x p e r i e n c e da nNmX
epidemic while the epidemic in neighboring Titao district was due to
NmA, suggests that clonal waves of meningococcal strains, as
described in northern Ghana [6], can be specific to relatively small
populations. The highly localized dynamic of the Kozah outbreak
also lends some support to this hypothesis. Competition between
colonizing meningococcal strains may play a role in such variations
and may, in addition, define which serogroup will be predominant
during an epidemic,ifseveral strains are circulating in the population.
This may explain why in all districts during epidemics observed so far
(Togo, Burkina Faso, Niger), incidence was high for only a single
serogroup at a time. The widespread reactive mass campaigns with
serogroup A/C polysaccharide vaccine in Burkina Faso is unlikely to
have played a role in the serogroup distribution during epidemics, as
polysaccharide vaccines probably lack impact on meningococcal
carriage [20]. To better understand the relation between epidemic
serogroups, further research should include surveillance at the health
center level during epidemics, ideally with frequent multi-locus
sequence typing of isolates and carriage studies from a larger area.
To eliminate epidemic NmA meningitis in sub-Saharan Africa, a
meningococcal serogroup A conjugate vaccine (MenAfriVac) is
being introduced in Burkina Faso, Mali and Niger [21,22]. Our
data have several implications for the impact assessment of this
vaccine which currently is designed to use national surveillance
data from Burkina Faso. However, the low contribution of NmAt o
meningococcal disease during recent compared to previous years,
occurring already before vaccine introduction, will make it difficult
to quantify the impact of group A conjugate vaccine on incidence
or case counts, and only data from exhaustive long-term
laboratory surveillance comparing the previous to the coming
decade may allow an assessment. Our finding of localized NmX
epidemics underlines the need for widespread, not only sentinel,
laboratory surveillance with systematic serogrouping of meningo-
coccal cases, including identification of serogroup X. Continuous
high-quality laboratory surveillance over several years also is
necessary to survey for serogroup replacement. Since serogroup A
conjugate vaccine is expected to impact meningococcal carriage
[23], introduction of a group A conjugate vaccine could select for
the spread of other Nm serogroups, although the currently
infrequent colonization with NmA [15] suggests that the risk for
replacement is low.
Some conclusions from the presented analysis may be limited by
small numbers of cases evaluated during outbreak investigation.
Most importantly, the incidence estimation for the Se ´gue ´ne ´ga
epidemic in 2010 is based on laboratory evaluation of six suspected
cases. However, additional comparable surveillance data from the
Pediatric University Hospital Charles-de-Gaulle, Ouagadougou
suggest a similar proportion of suspected cases being NmX (49 NmX
among 66 suspected cases, 74%) [Delrieu et al., 17
th International
Pathogenic Neisseria Conference; Banff, Canada; 2010 Sep 11–16;
abstract OM11]. Other conclusions may be biased because
surveillance activities only included limited time periods and some
activities were passive or targeted outbreak evaluations. However,
appropriate laboratory methods had been used throughout the
reported period and for most activities, including outbreak
investigations, data from at least three observation years were
available.Also,previousreportsfromthisdecadedescribedsimilarly
low incidences of NmX cases [7,10,18,24]. We acknowledge that the
interpretation of data from such a variety of surveillance systems is
difficult. However, we estimate that these data are the most
exhaustive and precise information available from the two
countries. The local operational and financial constraints are such
that one unified surveillance system with exhaustive laboratory
analysis in a wide geographic area has not existed during past years
and is challenging to establish.
In summary, our study showed that NmX can cause both
hyperendemic and epidemic meningitis in the meningitis belt,
while its potential to cause large epidemic waves remains unclear.
This underlines that despite ongoing serogroup A conjugate
vaccine introduction in some countries, control and prevention of
substantial meningitis epidemics due to any serogroup will require
ongoing quality surveillance, better understanding of the epidemic
meningitis phenomenon, continued vaccine development and
support to case management.
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